Table 4.
Baseline Characteristics of Patients with Multi-Line Therapies, According to in MDT Group or Not
| Characteristics | All (N=135) | MDT Group (N=79) | Non-MDT Group (N=56) | P value |
|---|---|---|---|---|
| Age, median (IQR) | 54.0 (46.0, 62.0) | 54.0 (48.0, 61.0) | 52.5 (40.5, 65.5) | 0.735 |
| < 50, No. (%) | 46 (34.1%) | 26 (32.9%) | 20 (35.7%) | |
| ≥ 50, No. (%) | 89 (65.9%) | 53 (67.1%) | 36 (64.3%) | |
| Gender, No. (%) | 0.323 | |||
| Female | 35 (25.9%) | 18 (22.8%) | 17 (30.4%) | |
| Male | 100 (74.1%) | 61 (77.2%) | 39 (69.6%) | |
| Histological type, No. (%) | 0.253 | |||
| ccRCC | 94 (69.6%) | 52 (65.8%) | 42 (75.0%) | |
| Non- ccRCC | 41 (30.4%) | 27 (34.2%) | 12 (25.0%) | |
| cT stage, No. (%) | 0.793 | |||
| 1–2 | 73 (54.1%) | 43 (54.4%) | 30 (53.6%) | |
| 3–4 | 50 (37.0%) | 28 (35.4%) | 22 (39.3%) | |
| NA | 12 (8.9%) | 8 (10.1%) | 4 (7.1%) | |
| ISUP, No. (%) | 0.856 | |||
| 1–2 | 28 (20.7%) | 16 (20.3%) | 12 (21.4%) | |
| 3–4 | 83 (61.5%) | 50 (63.3%) | 33 (58.9%) | |
| NA | 24 (17.8%) | 13 (16.5%) | 11 (19.6%) | |
| Nephrectomy, No. (%) | 0.209 | |||
| Yes | 121 (89.6%) | 73 (92.4%) | 48 (85.7%) | |
| No | 14 (10.4%) | 6 (7.6%) | 8 (14.3%) | |
| IMDC, No. (%) | 0.495 | |||
| Low risk (0) | 22 (16.3%) | 12 (15.2%) | 10 (17.9%) | |
| Intermediate risk (1–2) | 96 (71.1%) | 59 (74.7%) | 37 (66.1%) | |
| High risk (≥ 3) | 17 (12.6%) | 8 (10.1%) | 9 (16.1%) | |
| Interval from diagnosis to metastasis, No. (%) | 0.969 | |||
| Metachronous | 60 (44.4%) | 25 (44.6%) | 35 (44.3%) | |
| Synchronous | 75 (55.6%) | 31 (55.4%) | 44 (55.7%) | |
| Metastatic site, No. (%) | ||||
| Lung | 75 (55.6%) | 38 (48.1%) | 37 (66.1%) | 0.038 |
| Bone | 47 (34.8%) | 28 (35.4%) | 19 (33.9%) | 0.478 |
| Liver | 17 (12.6%) | 8 (10.1%) | 9 (16.1%) | 0.305 |
| Brain | 6 (4.4%) | 2 (2.5%) | 4 (7.1%) | 0.2 |
| Lymph node | 41 (30.4%) | 23 (29.1%) | 18 (32.1%) | 0.706 |
| Other | 51 (37.8%) | 29 (36.7%) | 22 (39.3%) | 0.204 |
| Number of metastatic organs, No. (%) | 0.412 | |||
| Single | 61 (45.2%) | 38 (48.1%) | 23 (41.1%) | |
| Multiple (≥ 2 sites) | 74 (54.8%) | 41 (51.9%) | 33 (58.9%) | |
| Metastasis resection, No. (%) | 0.679 | |||
| Yes | 22 (16.3%) | 12 (15.2%) | 10 (17.9%) | |
| No | 113 (83.7%) | 67 (84.8%) | 46 (82.1%) |
Abbreviations: MDT, Multidisciplinary team; ccRCC, Clear cell renal cell carcinoma; ISUP, international society of urological pathology; IMDC, International Metastatic renal cell carcinoma Database Consortium.